Among the various treatments mentioned in Table 3, two PPAR agonists, elafibranor and seladelpar, have completed phase 3 trials and gained approval for the treatment of PBC patients in 2024 [171]. This evidence concerns the gene PPARA and primary biliary cholangitis.